A systematic review of oral methotrexate for multiple sclerosis
Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials i...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2006-08, Vol.12 (4), p.507-510 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 510 |
|---|---|
| container_issue | 4 |
| container_start_page | 507 |
| container_title | Multiple sclerosis |
| container_volume | 12 |
| creator | Gray, O M McDonnell, G V Forbes, R B |
| description | Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only. This trial reported a non-significant reduction in sustained Expanded Disability Status Scale (EDSS) progression and number of relapses in favour of methotrexate therapy. There were no data on relapse rate and no difference in time to first relapse. Minor side-effects were reported in both methotrexate (87.1%) and placebo groups (89.7%), but there were no major side-effects. Further trials are required in both relapsing-remitting and progressive groups to establish the role of oral methotrexate in MS. |
| doi_str_mv | 10.1191/1352458506ms1299oa |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68732575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_1352458506ms1299oa</sage_id><sourcerecordid>19480213</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-91c7635215429b693b5ea2c85b8d0248ef3ba493848a028e640b399197a0347c3</originalsourceid><addsrcrecordid>eNqF0VtLwzAUAOAgitPpH_BBgqBvdbk2yZOM4Q0GvuhzSbNT7WiXmbTq_r0ZGwwUlDwkge8k54LQGSXXlBo6olwyIbUkeRspM8bbPXREhVIZMYrsp3MC2VoM0HGMc0KIUlweogHNTTrn-RG6GeO4ih20tqsdDvBRwyf2FfbBNriF7s13Ab5sB7jyAbd909XLBnB0DQQf63iCDirbRDjd7kP0cnf7PHnIpk_3j5PxNHOCmS4z1Kk8ZUNlupa54aUEy5yWpZ4RJjRUvLTCcC20JUxDLkjJjaFGWcKFcnyIrjbvLoN_7yF2RVtHB01jF-D7WORacSaV_BdSIzRhlCd48QPOfR8WqYiCUa1Tf6RJiG2QS9XGAFWxDHVrw6qgpFgPofg9hBR0vn25L1uY7UK2XU_gcgtsdLapgl24Ou6cMprTtIZotHHRvsIuvT--_gb9JZv3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218800759</pqid></control><display><type>article</type><title>A systematic review of oral methotrexate for multiple sclerosis</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Gray, O M ; McDonnell, G V ; Forbes, R B</creator><creatorcontrib>Gray, O M ; McDonnell, G V ; Forbes, R B</creatorcontrib><description>Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only. This trial reported a non-significant reduction in sustained Expanded Disability Status Scale (EDSS) progression and number of relapses in favour of methotrexate therapy. There were no data on relapse rate and no difference in time to first relapse. Minor side-effects were reported in both methotrexate (87.1%) and placebo groups (89.7%), but there were no major side-effects. Further trials are required in both relapsing-remitting and progressive groups to establish the role of oral methotrexate in MS.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1191/1352458506ms1299oa</identifier><identifier>PMID: 16900766</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Administration, Oral ; Biological and medical sciences ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Humans ; Immunomodulators ; Immunosuppressive Agents - administration & dosage ; Medical sciences ; Methotrexate - administration & dosage ; Multiple Sclerosis - drug therapy ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic</subject><ispartof>Multiple sclerosis, 2006-08, Vol.12 (4), p.507-510</ispartof><rights>2007 INIST-CNRS</rights><rights>2006 Arnold</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-91c7635215429b693b5ea2c85b8d0248ef3ba493848a028e640b399197a0347c3</citedby><cites>FETCH-LOGICAL-c429t-91c7635215429b693b5ea2c85b8d0248ef3ba493848a028e640b399197a0347c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/1352458506ms1299oa$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/1352458506ms1299oa$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17983131$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16900766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gray, O M</creatorcontrib><creatorcontrib>McDonnell, G V</creatorcontrib><creatorcontrib>Forbes, R B</creatorcontrib><title>A systematic review of oral methotrexate for multiple sclerosis</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only. This trial reported a non-significant reduction in sustained Expanded Disability Status Scale (EDSS) progression and number of relapses in favour of methotrexate therapy. There were no data on relapse rate and no difference in time to first relapse. Minor side-effects were reported in both methotrexate (87.1%) and placebo groups (89.7%), but there were no major side-effects. Further trials are required in both relapsing-remitting and progressive groups to establish the role of oral methotrexate in MS.</description><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Medical sciences</subject><subject>Methotrexate - administration & dosage</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0VtLwzAUAOAgitPpH_BBgqBvdbk2yZOM4Q0GvuhzSbNT7WiXmbTq_r0ZGwwUlDwkge8k54LQGSXXlBo6olwyIbUkeRspM8bbPXREhVIZMYrsp3MC2VoM0HGMc0KIUlweogHNTTrn-RG6GeO4ih20tqsdDvBRwyf2FfbBNriF7s13Ab5sB7jyAbd909XLBnB0DQQf63iCDirbRDjd7kP0cnf7PHnIpk_3j5PxNHOCmS4z1Kk8ZUNlupa54aUEy5yWpZ4RJjRUvLTCcC20JUxDLkjJjaFGWcKFcnyIrjbvLoN_7yF2RVtHB01jF-D7WORacSaV_BdSIzRhlCd48QPOfR8WqYiCUa1Tf6RJiG2QS9XGAFWxDHVrw6qgpFgPofg9hBR0vn25L1uY7UK2XU_gcgtsdLapgl24Ou6cMprTtIZotHHRvsIuvT--_gb9JZv3</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>Gray, O M</creator><creator>McDonnell, G V</creator><creator>Forbes, R B</creator><general>SAGE Publications</general><general>Arnold</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20060801</creationdate><title>A systematic review of oral methotrexate for multiple sclerosis</title><author>Gray, O M ; McDonnell, G V ; Forbes, R B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-91c7635215429b693b5ea2c85b8d0248ef3ba493848a028e640b399197a0347c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Medical sciences</topic><topic>Methotrexate - administration & dosage</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gray, O M</creatorcontrib><creatorcontrib>McDonnell, G V</creatorcontrib><creatorcontrib>Forbes, R B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gray, O M</au><au>McDonnell, G V</au><au>Forbes, R B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A systematic review of oral methotrexate for multiple sclerosis</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>12</volume><issue>4</issue><spage>507</spage><epage>510</epage><pages>507-510</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only. This trial reported a non-significant reduction in sustained Expanded Disability Status Scale (EDSS) progression and number of relapses in favour of methotrexate therapy. There were no data on relapse rate and no difference in time to first relapse. Minor side-effects were reported in both methotrexate (87.1%) and placebo groups (89.7%), but there were no major side-effects. Further trials are required in both relapsing-remitting and progressive groups to establish the role of oral methotrexate in MS.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>16900766</pmid><doi>10.1191/1352458506ms1299oa</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2006-08, Vol.12 (4), p.507-510 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68732575 |
| source | MEDLINE; SAGE Complete |
| subjects | Administration, Oral Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Humans Immunomodulators Immunosuppressive Agents - administration & dosage Medical sciences Methotrexate - administration & dosage Multiple Sclerosis - drug therapy Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology Pharmacology. Drug treatments Randomized Controlled Trials as Topic |
| title | A systematic review of oral methotrexate for multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T06%3A53%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20systematic%20review%20of%20oral%20methotrexate%20for%20multiple%20sclerosis&rft.jtitle=Multiple%20sclerosis&rft.au=Gray,%20O%20M&rft.date=2006-08-01&rft.volume=12&rft.issue=4&rft.spage=507&rft.epage=510&rft.pages=507-510&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1191/1352458506ms1299oa&rft_dat=%3Cproquest_cross%3E19480213%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218800759&rft_id=info:pmid/16900766&rft_sage_id=10.1191_1352458506ms1299oa&rfr_iscdi=true |